Halozyme Therapeutics Abandons $2.1 Billion Acquisition Bid for Evotec Due to Lack of Engagement

Withdrawal of Bid:
Halozyme Therapeutics has withdrawn its $2.1 billion (€2 billion) acquisition bid for Evotec SE, a German drug developer[1][2][3].

Reason for Withdrawal:
The bid was withdrawn due to Evotec's unwillingness to engage in discussions about the potential acquisition[2][3].

Failed Attempts:
Halozyme made multiple attempts to engage with Evotec but was met with a lack of dialogue, leading to the withdrawal of the bid[3].

Date of Withdrawal:
The bid was withdrawn on November 22, 2024[2][3].